Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Indiana: - Northwest Cancer Center - Crown Point — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Northwest Cancer Center - Hobart — Hobart, Indiana
- Saint Mary Medical Center — Hobart, Indiana
- The Community Hospital — Munster, Indiana
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Indiana: - Community Health Network, Inc — Indianapolis, Indiana
- Community Health Network, Inc. — Indianapolis, Indiana
- Community Health Network, Inc. — Indianapolis, Indiana
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Indiana: - Research Site — Fort Wayne, Indiana
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Indiana: - Northwest Cancer Center - Crown Point — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Saint Mary Medical Center — Hobart, Indiana
- Saint Catherine Hospital — Indianapolis, Indiana
- The Community Hospital — Munster, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Indiana: - Research Site — Noblesville, Indiana
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana
- Indiana University Health University Hospital — Indianapolis, Indiana
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Indiana: - Franciscan Health ( Site 0219) — Indianapolis, Indiana
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Indiana: - Northwest Cancer Centers, P.C. — Dyer, Indiana
- Parkview Research Center at Parkview Regional Medical Center — Fort Wayne, Indiana
- Local Institution - 0423 — Munster, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Indiana: - Northwest Cancer Centers, P.C. — Dyer, Indiana
Phase 3 Recruiting Industry
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT07365241
Sites in Indiana: - Franciscan St. Francis Health /ID# 279788 — Indianapolis, Indiana
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in Indiana: - Parkview Packnett Family Cancer Institute — Fort Wayne, Indiana
- Franciscan Health Indianapolis — Indianapolis, Indiana
Phase 3 Recruiting Industry
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Indiana: - Indiana University Health Arnett Cancer Center ( Site 0116) — Lafayette, Indiana
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Indiana: - Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in Indiana: - UChicago Medicine Northwest Indiana — Crown Point, Indiana
Phase 1, Phase 2 Recruiting Industry
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disea…
Sponsor: AbbVie
NCT ID: NCT06772623
Sites in Indiana: - Parkview Comprehensive Cancer Center /ID# 271879 — Fort Wayne, Indiana
- Community Health Network /ID# 273437 — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase …
Sponsor: Frontier Medicines Corporation
NCT ID: NCT06244771
Sites in Indiana: - Northwest Cancer Centers — Dyer, Indiana
Phase 1, Phase 2 Recruiting Industry
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Sponsor: IDEAYA Biosciences
NCT ID: NCT07174583
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office — Fort Wayne, Indiana
Phase 2 Recruiting Industry
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT07155174
Sites in Indiana: - Fort Wayne Medical Oncology And Hematology /ID# 277336 — Fort Wayne, Indiana
Phase 1, Phase 2 Recruiting Federal
Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Participants will receive either a combinati…
Sponsor: VA Office of Research and Development
NCT ID: NCT06681220
Sites in Indiana: - Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plu…
Sponsor: Hirva Mamdani
NCT ID: NCT05903092
Sites in Indiana: - Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Indiana: - UChicago Medicine - Northwest Indiana — Crown Point, Indiana
- Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
- Community Health Network, Inc — Indianapolis, Indiana
- Community Health Network, Inc. — Indianapolis, Indiana
- Community Health Network Investigational Drug Services — Indianapolis, Indiana
Phase 1 Recruiting Industry
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how …
Sponsor: Eli Lilly and Company
NCT ID: NCT07046923
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Indiana: - Woodland Cancer Care Center — Michigan City, Indiana
- Reid Health — Richmond, Indiana
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Indiana: - Parkview Research Center — Fort Wayne, Indiana